Adidas, Puma Shares Fall as Dick’s Sporting Goods Cuts Outlook 
Luxshare Shares Rise as First-Half Profit Jumps 18% 
Trump Administration Plans New Drug Pricing Deals With Biotech Firms 
Tesla Raises Cybertruck Prices by $5,000 in US 
Australia’s Big Four Banks Face Mortgage Slowdown as Valuations Draw Scrutiny 
SEC Probes Banks Over Situational Awareness Hedge Fund Collapse 
Woodside Drops $5 Billion Clean Energy Plan as Profit Rises 7% 
SK Hynix Shares Fall as Workers Reject Wage Deal 
HP Stock Drops 9% Despite Q3 Earnings Beat and Raised 2026 Outlook 
Nvidia Revenue Soars 106% as AI Demand Hits ‘Inflection Point’ 
Trump Buys SpaceX Shares After Record IPO 
SK Biopharmaceuticals Secures Global Rights to Biohaven Epilepsy Drug Opakalim 
BNP Paribas, KB Kookmin Eye $2 Billion Techcombank Stake 
Meta Agrees to $18 Billion Settlement, Tightens Teen Social Media Rules 
Trian Drops Wendy’s Take-Private Bid Plans, Shares Plunge 14% 
Salesforce Shares Surge as AI Demand Powers Q2 Earnings Beat 
Add as a preferred source on Google
MINNEAPOLIS, April 23, 2018 -- Inspire Medical Systems, Inc. (“Inspire”), a medical technology company focused on the development and commercialization of innovative and minimally invasive solutions for patients with obstructive sleep apnea, announced today that it has commenced an initial public offering of 5,000,000 shares of its common stock. Inspire also expects to grant the underwriters a 30-day option to purchase an additional 750,000 shares of its common stock. The initial public offering price is expected to be between $14.00 and $16.00 per share. All shares of common stock to be sold in the proposed offering will be sold by Inspire. Inspire has been approved to list its common stock on the New York Stock Exchange under the ticker symbol “INSP.”
BofA Merrill Lynch and Goldman Sachs & Co. LLC are serving as joint book-running managers for the proposed offering. Guggenheim Securities, Stifel, and Wells Fargo Securities are acting as co-managers for the proposed offering.
The offering will be made only by means of a prospectus. A copy of the preliminary prospectus relating to this offering, when available, may be obtained from BofA Merrill Lynch, NC1-004-03-43, 200 North College Street, 3rd Floor, Charlotte, NC 28255-0001, Attention: Prospectus Department or via email: [email protected]; and from Goldman Sachs & Co. LLC, Attention: Prospectus Department, 200 West Street, New York, New York 10282, via telephone: 1-866-471-2526, or via email: [email protected].
A registration statement on Form S-1 relating to these securities has been filed with the U.S. Securities and Exchange Commission but has not yet become effective. These securities may not be sold nor may offers to buy these securities be accepted prior to the time the registration statement becomes effective. This press release shall not constitute an offer to sell or the solicitation of an offer to buy nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.
About Inspire Medical Systems
Inspire is a medical technology company focused on the development and commercialization of innovative and minimally invasive solutions for patients with obstructive sleep apnea. Inspire Medical Systems’ proprietary Inspire therapy is the first and only FDA-approved neurostimulation technology that provides a safe and effective treatment for moderate to severe obstructive sleep apnea.
Inspire Investor and Media Contact
Bob Yedid
LifeSci Advisors
[email protected]
646-597-6989
